Trending stocks today
The Panic-Proof Portfolio (Stockchase Research)
By Michael O'Reilly at Stockchase Premium
Member since: Jul '20 · 2816 Opinions
Rating Card
| All | 
Rating
| 
Big Win
| 
Win
| 
Neutral
| 
Loss
| 
Big Loss
|  |
|---|---|---|---|---|---|---|---|
| 5 | 892 22.55% | 974 24.63% | 566 14.31% | 939 23.74% | 584 14.77% | ||
| 1 Month | 5 | 110 9.08% | 418 34.52% | 302 24.94% | 358 29.56% | 23 1.90% | |
| 6 Months | 5 | 266 24.29% | 270 24.66% | 152 13.88% | 257 23.47% | 150 13.70% | |
| 12 Months | 5 | 280 28.99% | 193 19.98% | 67 6.94% | 208 21.53% | 218 22.57% | |
| 2 Years | 5 | 236 34.55% | 93 13.62% | 45 6.59% | 116 16.98% | 193 28.26% |
Stock Opinions by The Panic-Proof Portfolio (Stockchase Research)
$90.160
Unknown
This large global biopharma company has reported continued success in a oncology based treatment for a blood cancer effecting 180,000 new patients annually. The company is building cash reserves while debt is retired. It trades at 22x earnings and supports a 21% ROE. We recommend setting a stop-loss at $27, looking to achieve $45 -- upside potential of 26%. Yield 4.5%
(Analysts’ price target is $45.07)LDOS provides cybersecurity and defense solutions to US governments. They were just awarded a $670 million hypersonic missile research contract. It trades at 17x earnings and supports a 27% ROE. We like that cash reserves are growing, while debt is retired and shares bought back. We recommend setting a stop-loss at $125, looking to achieve $192 -- upside potential of 24%. Yield 1.0%
(Analysts’ price target is $192.17)Our PAST TOP PICK with ESEA has triggered its stop at $36. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 9%, when combined with our previous guidance.
Our PAST TOP PICK with VIRC has triggered its stop at $12. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 16%, when combined with our previous guidance.
RPRX partners with pharma companies like Bristol-Myers to help fund development in exchange for collecting royalties. It pays a good dividend, backed by a payout ratio under 33% of cash flow. It trades at 10x earnings, under 2x book and supports a 17% ROE. Its portfolio grew by 15% this year. We recommend setting a stop-loss at $22, looking to achieve $33 -- upside potential of 28%. Yield 3.2%
(Analysts’ price target is $41.53)CMCSA released some worrisome news that they expect to continue to lose customers to growing competition. However, they are managing a strategy to off load some of its services and has also announced a partnership with Warner Bros that could open some new revenue streams. We like that cash reserves are growing as debt is retired and shares bought back. It trades at 12x earnings, under 2x book and supports a 17% ROE. We recommend setting a stop-loss at $35, looking to achieve $48 -- upside potential of 20%. Yield 3.1%
(Analysts’ price target is $48.14)ONIT provides direct lending for traditional and reverse mortgages to customers in the US, Philippines and India. We like that cash reserves are staying steady as the company retired higher rate notes in exchange for longer term debt. It trades at 22x earnings, under book value and supports a 21% ROE. We recommend setting a stop-loss at $29, looking to achieve $45 -- upside potential of 34%. Yield 0%
(Analysts’ price target is $45.00)Our PAST TOP PICK with GSY has triggered its stop at $165. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment loss of 7%.
Two of the largest advertising companies in the US just paired up under the OMC name in a $13.2 billion all stock deal. The new entity will represent 48% of ad revenue and OMC management expects $750 million in annual cost savings. It trades at 13x earnings and supports a ROE of 33%. We recommend setting a stop-loss at $80, looking to achieve $116 -- upside potential of 28%. Yield 3.0%
(Analysts’ price target is $116.02)